Literature DB >> 11510803

Comparison of the standard gamble, rating scale, AQLQ and SF-36 for measuring quality of life in asthma.

E F Juniper1, G R Norman, F M Cox, J N Roberts.   

Abstract

With interest in health economics growing, there is a demand for valid methods for measuring health-related quality of life (HRQL) in asthma using utilities. The aims of this study were to develop disease-specific versions of the standard gamble and rating scale, to compare their measurement properties with those of the Asthma Quality of Life Questionnaire (AQLQ) and the Medical Outcomes Survey Short-Form 36 (SF-36), as well as to determine their validity for assessing asthma-specific quality of life. Forty adults with symptomatic asthma participated in a 9-week observational study. Participants completed the standard gamble, rating scale, AQLQ, SF-36 and other measures of clinical asthma status at baseline and after 1, 5 and 9 weeks. In patients whose asthma was stable between assessments, reliability was good for the rating scale (intraclass correlation coefficient (ICC)=0.89) and the AQLQ (ICC=0.95) but more modest for the SF-36 mental score (ICC=0.68), SF-36 physical score (ICC=0.65) and standard gamble (ICC=0.59). The responsiveness index was highest in the AQLQ (1.35), followed by the rating scale (0.74), the physical score of the SF-36 (0.61) and the standard gamble (0.31). Construct validity (correlation with other indices of health status) was strongest for the AQLQ and the rating scale. In conclusion, both the disease-specific rating scale and the Asthma Quality of Life Questionnaire have strong measurement properties for measuring asthma-specific quality of life; the Short-Form 36 health survey physical summary score has more modest properties. Although the disease-specific standard gamble has acceptable discriminative properties, its evaluative properties are too inadequate for it to be used in cost/utility analyses. Poor correlation between the standard gamble and the rating scale indicates that utilities cannot be derived from rating scale data.

Entities:  

Mesh:

Year:  2001        PMID: 11510803     DOI: 10.1183/09031936.01.00088301

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  24 in total

1.  An 18-item standardized Asthma Quality of Life Questionnaire-AQLQ(S).

Authors:  Eirini Grammatopoulou; Emmanouil Skordilis; Dimitra Koutsouki; George Baltopoulos
Journal:  Qual Life Res       Date:  2007-12-14       Impact factor: 4.147

Review 2.  Recommendations on chronic constipation (including constipation associated with irritable bowel syndrome) treatment.

Authors:  P Paré; Ronald Bridges; Malcolm C Champion; Subhas C Ganguli; James R Gray; E Jan Irvine; Victor Plourde; Pierre Poitras; Geoffrey K Turnbull; Paul Moayyedi; Nigel Flook; Stephen M Collins
Journal:  Can J Gastroenterol       Date:  2007-04       Impact factor: 3.522

3.  Feasibility, comparability, and reliability of the standard gamble compared with the rating scale and time trade-off techniques in Korean population.

Authors:  Seon-Ha Kim; Sang-Il Lee; Min-Woo Jo
Journal:  Qual Life Res       Date:  2017-08-11       Impact factor: 4.147

Review 4.  Asthma outcomes: quality of life.

Authors:  Sandra R Wilson; Cynthia S Rand; Michael D Cabana; Michael B Foggs; Jill S Halterman; Lynn Olson; William M Vollmer; Rosalind J Wright; Virginia Taggart
Journal:  J Allergy Clin Immunol       Date:  2012-03       Impact factor: 10.793

5.  Construction of the Pediatric Asthma Impact Scale (PAIS) for the Patient-Reported Outcomes Measurement Information System (PROMIS).

Authors:  Karin B Yeatts; Brian Stucky; David Thissen; Deb Irwin; James W Varni; Esi Morgan DeWitt; Jin-Shei Lai; Darren A DeWalt
Journal:  J Asthma       Date:  2010-04       Impact factor: 2.515

6.  Responsiveness of generic health-related quality of life measures in stroke.

Authors:  A Simon Pickard; Jeffrey A Johnson; David H Feeny
Journal:  Qual Life Res       Date:  2005-02       Impact factor: 4.147

7.  Utilities and disutilities for attributes of injectable treatments for type 2 diabetes.

Authors:  Kristina S Boye; Louis S Matza; Kimberly N Walter; Kate Van Brunt; Andrew C Palsgrove; Aodan Tynan
Journal:  Eur J Health Econ       Date:  2010-03-12

8.  The role of panic-fear in comorbid asthma and panic disorder.

Authors:  Jonathan M Feldman; Mahmood I Siddique; Nigel S Thompson; Paul M Lehrer
Journal:  J Anxiety Disord       Date:  2008-07-01

9.  Psychometric and utility-based measures of health status of asthmatic patients with different disease control level.

Authors:  Agota Szende; Klas Svensson; Elisabeth Ståhl; Agnes Mészáros; Gyula Y Berta
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

10.  Utilities and disutilities for type 2 diabetes treatment-related attributes.

Authors:  Louis S Matza; Kristina S Boye; Nicole Yurgin; Jessica Brewster-Jordan; Sally Mannix; Jodi M Shorr; Beth L Barber
Journal:  Qual Life Res       Date:  2007-07-19       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.